Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06655155 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
A Phase 2 study of Systemic Sclerosis (SSc), sponsored by argenx.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
- 20
- Study locations
NCT06655155 is a Phase 2 study of Systemic Sclerosis (SSc) that is actively recruiting participants, run by argenx. The registered enrollment target is 81 participants, below the 92-participant average among 8 other Systemic Sclerosis (SSc) trials with a reported enrollment target (12% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT06655155, a Phase 2 study of Systemic Sclerosis (SSc), is actively recruiting participants, sponsored by argenx.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the effect and safety of efgartigimod PH20 SC compared to placebo in adults with systemic sclerosis. The study consists of a screening period, a treatment period of up to 48 weeks and a safety follow-up period. After the screening period, eligible participants will be randomized in a 2:1 ratio to receive either efgartigimod PH20 SC or placebo. The total study duration can be up to approximately 15 months. More information can be found on: https://clinicaltrials.argenx.com/esscape
Conditions Studied
Interventions
- COMBINATION_PRODUCT Efgartigimod PH20 SC
- OTHER Placebo PH20 SC
Study Locations (20)
Other
- Aprillus Asistencia e Investigacion - Buenos Aires
- Instituto de Investigación Clínica TyT - Buenos Aires
- Consultorios Médicos Dr. Doreski - Fundacion Respirar - Buenos Aires
- Hospital General de Agudos Dr. José María Ramos Mejia - Buenos Aires
- Sanatorio Allende S.A. - Córdoba
- Clínica Mayo de U.M.C.B. S.R.L - San Miguel de Tucumán
- Centro de Investigaciones Médicas Tucumán - San Miguel de Tucumán
- UZ Gent - Ghent
- UZ Brussel - Jette
- Medical Center Artmed OOD - Plovdiv
- Diagnostic Consultative Center Convex EOOD - Sofia
Maryland
- Johns Hopkins Asthma and Allergy Center - Baltimore
- Thomas Jefferson University - Columbia
Arizona
- Arizona Arthritis and Rheumatology Associates - Phoenix
California
- UCLA Ronald Reagan University of California Los Angeles Medical Center - Los Angeles
Florida
- IRIS Research and Development LLC - Plantation
Illinois
- University of Illinois Health Outpatient Care Center - Chicago
Louisiana
- DelRicht Research, LLC - New Orleans
Michigan
- University of Michigan Hospital - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2024-11-11 |
| Est. Completion | 2027-06-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06655155
The ClinicalTrials.gov registry entry for NCT06655155 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 92-participant average among 8 other Systemic Sclerosis (SSc) trials with a reported enrollment target (12% lower). The listed sponsor is argenx, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Systemic Sclerosis (SSc) appearing as the primary indexed condition, and to 2 interventions - of which Efgartigimod PH20 SC is the first listed.
NCT06655155 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, Maryland, Arizona.
Frequently Asked Questions
What is clinical trial NCT06655155 about?
NCT06655155 is a clinical study titled "A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis". The main purpose of this study is to evaluate the effect and safety of efgartigimod PH20 SC compared to placebo in adults with systemic sclerosis. The study consists of a screening period, a treatment period of up to 48 weeks and a safety follow-up period. After the screening period, eligible partic...
What is the current status of trial NCT06655155?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2024-11-11. Estimated completion is 2027-06-14.
What conditions does trial NCT06655155 study?
This clinical trial studies the following conditions: Systemic Sclerosis (SSc).
What interventions are being tested in trial NCT06655155?
The interventions under investigation include: Efgartigimod PH20 SC (COMBINATION_PRODUCT), Placebo PH20 SC (OTHER).
Who is sponsoring clinical trial NCT06655155?
This trial is sponsored by argenx, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06655155 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Sclerosis (SSc)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
RECRUITING · Phase 2
-
Intralesional Injection of STS in Treatment of Calcinosis
RECRUITING · Phase 2
-
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
RECRUITING · Phase 2
-
Quantification of Calcinosis Cutis Disease Burden Using Computed Tomography Images
RECRUITING
-
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
RECRUITING · Phase 1
-
The Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of Life
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.